124 related articles for article (PubMed ID: 38468827)
1. Antibody Response to Breakthrough SARS-CoV-2 Infection in "Booster" Vaccinated Patients with Multiple Myeloma According to B/T/NK Lymphocyte Absolute Counts and anti-CD38 Treatments.
Sgherza N; Mestice A; Larocca AMV; Musto P
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024022. PubMed ID: 38468827
[No Abstract] [Full Text] [Related]
2. Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment.
Ghandili S; Schönlein M; Lütgehetmann M; Schulze Zur Wiesch J; Becher H; Bokemeyer C; Sinn M; Weisel KC; Leypoldt LB
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359701
[TBL] [Abstract][Full Text] [Related]
3. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
4. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
Aleman A; van Kesteren M; Zajdman AK; Srivastava K; Cognigni C; Mischka J; Chen LY; Upadhyaya B; Serebryakova K; Nardulli JR; Lyttle N; Kappes K; Jackson H; Gleason CR; Oostenink A; Cai GY; Van Oekelen O; ; van Bakel H; Sordillo EM; Cordon-Cardo C; Merad M; Jagannath S; Wajnberg A; Simon V; Parekh S
EBioMedicine; 2023 Dec; 98():104886. PubMed ID: 37995467
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
6. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia.
Fu JYL; Pukhari MH; Bador MK; Sam IC; Chan YF
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112825
[TBL] [Abstract][Full Text] [Related]
7. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients.
Piñana JL; Vazquez L; Calabuig M; López-Corral L; Martin-Martin G; Villalon L; Sanz-Linares G; Conesa-Garcia V; Sanchez-Salinas A; Gago B; Facal A; Risco-Gálvez I; Olave MT; Espigado I; Lopez-Jimenez J; Hernández-Rivas JÁ; Avendaño-Pita A; Arroyo I; Ferrer E; García-Cadenas I; González-Santillana C; Roldán-Pérez A; Ferrer B; Guerreiro M; Suarez-Lledó M; Camara A; Campos-Beltrán D; Navarro D; Cedillo Á; Sureda A; Solano C; ; Martino R
Blood Cancer J; 2023 Jan; 13(1):8. PubMed ID: 36599843
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and Serological Analysis of a SARS-CoV-2 Outbreak in a Nursing Home: Impact of SARS-CoV-2 Vaccination and Enhanced Neutralizing Immunity Following Breakthrough Infection.
Streibl BI; Lahne H; Grahl A; Agsten P; Bichler M; Büchl C; Damzog M; Eberle U; Gärtner S; Hobmaier B; Margos G; Hoch M; Jungnick S; Jonas W; Katz K; Laubert L; Schutt B; Seidl C; Treis B; Weindl D; Zilch K; Wildner M; Liebl B; Ackermann N; Sing A; Fingerle V
Microorganisms; 2022 Sep; 10(9):. PubMed ID: 36144413
[TBL] [Abstract][Full Text] [Related]
9. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
10. Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.
Terao T; Yamashita T; Fukumoto A; Kamura Y; Ikeda D; Kuzume A; Tabata R; Tsushima T; Miura D; Narita K; Takeuchi M; Doi M; Umezawa Y; Otsuka Y; Takamatsu H; Matsue K
Int J Hematol; 2022 May; 115(5):737-747. PubMed ID: 35190963
[TBL] [Abstract][Full Text] [Related]
11. Long-Term SARS-CoV-2-Specific Humoral and T Cell Responses after the BNT162b2 or BBIBP-CorV Booster and the Incidence of Breakthrough Infections among Healthcare Workers.
Matula Z; Bekő G; Király V; Gönczi M; Zóka A; Baráth A; Uher F; Vályi-Nagy I
Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38276662
[TBL] [Abstract][Full Text] [Related]
12. Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Nelli F; Fabbri A; Botticelli A; Giannarelli D; Marrucci E; Fiore C; Virtuoso A; Berrios JRG; Scagnoli S; Pisegna S; Cirillo A; Panichi V; Massari A; Silvestri MA; Ruggeri EM
Front Oncol; 2023; 13():1280416. PubMed ID: 38023235
[TBL] [Abstract][Full Text] [Related]
13. Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Faustini SE; Hall A; Brown S; Roberts S; Hill H; Stamataki Z; ; Jenner MW; Owen RG; Pratt G; Cook G; Richter A; Drayson MT; Kaiser MF; Heaney JLJ
Br J Haematol; 2023 Jun; 201(5):845-850. PubMed ID: 36895158
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
[TBL] [Abstract][Full Text] [Related]
15. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
16. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
[TBL] [Abstract][Full Text] [Related]
17. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
Miyamoto S; Suzuki T
Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
[TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
19. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
[TBL] [Abstract][Full Text] [Related]
20. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]